瑞博生物-B(06938):RBD7022注射液即将于中国启动用于治疗高血脂症适应症的 III期临床试验
Last Update:
2 3 月, 2026
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.